Article

Atrial natriuretic peptide stability.

Albert Einstein College of Medicine, Division of Cardiology, Bronx, NY 10461, USA.
Clinical biochemistry (impact factor: 2.02). 06/2008; 41(14-15):1255-8. DOI:10.1016/j.clinbiochem.2008.05.008 pp.1255-8
Source: PubMed

ABSTRACT Atrial natriuretic peptide (ANP) is a key regulator in the homeostasis of water excretion and has emerged as an important prognostic marker for symptomatic chronic heart failure (CHF). The stability of ANP represents a crucial factor in assessing its use as a cardiac biomarker. Accordingly, we assessed the stability of ANP in blood samples collected from healthy controls and CHF subjects for a 12 month period.
Blood samples from 10 healthy controls and 12 symptomatic CHF subjects with left ventricular systolic dysfunction were drawn. Determination of plasma ANP was performed by a standardized radioimmunoassay protocol.
The ANP levels of healthy subjects were 68.5+/-11.6 pg/mL at baseline and 69.9+/-17.2 pg/mL at 12 months (p=0.71). The ANP concentrations of CHF subjects were 199.25+/-44.8 pg/mL at baseline and 197.83+/-47.4 pg/mL at 12 months (p=0.70) respectively.
ANP is a stable molecule with no evidence of degradation when stored at -80 degrees C.

0 0
 · 
0 Bookmarks
 · 
23 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

-80 degrees C
 
10 healthy controls
 
12 months
 
12 symptomatic CHF subjects
 
ANP concentrations
 
ANP levels
 
Atrial natriuretic peptide
 
blood samples
 
cardiac biomarker
 
CHF subjects
 
crucial factor
 
healthy controls
 
healthy subjects
 
key regulator
 
plasma ANP
 
prognostic marker
 
stable molecule
 
standardized radioimmunoassay protocol
 
symptomatic chronic heart failure
 
ventricular systolic dysfunction
 

Ronald Zolty